Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease

NCT07659353 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

320

Enrollment

OTHER

Sponsor class

Conditions

Chrohn's Disease

Interventions

DRUG: Mirikizumab
DRUG: Azathioprine (AZA)

Sponsor

University Hospital Schleswig-Holstein